Rapid Micro shares surge 16.05% intraday on major multi-system order from pharmaceutical client.

Rapid Micro Biosystems surged 16.05% intraday following its presentation at the Stifel 2025 Healthcare Conference, where the company highlighted a significant multi-system order from a major pharmaceutical client and its collaboration with Merck-MilliporeSigma. The announcement emphasized the GrowthDirect platform’s automation capabilities, cost savings, and expansion into North America, Europe, and Asia. The order, expected to drive revenue in Q4 2025, combined with five consecutive quarters of positive gross margins and a 20% annual revenue growth target, underscored strong market confidence. The strategic partnership with Merck was also cited as a key growth driver, enhancing market reach and margin expansion. These developments aligned with the stock’s sharp intraday rally, reflecting optimism about the company’s operational progress and financial trajectory.